The blockbuster era is drawing to a close and shorter runs and batch sizes are becoming commonplace, largely due to growth in emerging markets and the increased demand that this brings for a wide range of pharma products. This demand has shifted the focus somewhat, from production speeds to the ability to effect fast and efficient product changeovers and start-ups. One constant remains, however – products entering the supply chain must be 100% safe for patient use.